Cubist settles with TEVA on generic Cubicin. Cubist was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $22. Teva gets right to generic daptomycin MRSA product on 6/24/18 and admits Cubist patents are valid.
Cubist Pharmaceuticals Settles CUBICIN Patent Litigation with Teva
Cubist Licenses Cubicin Antibiotic to Teva in Patent Suit Settlement – Bloomberg